Company news
Kiniksa Pharmaceuticals International, Plc (NASDAQ:KNSA) news
Kiniksa Pharmaceuticals International, Plc news releases on 6ix. Latest, Jul 25, 2023: Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results…
Press releases — page 2
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution
July 24, 2023
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
July 16, 2023
Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 5, 2023
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution
May 1, 2023
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
April 30, 2023
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution
February 27, 2023
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
February 26, 2023
Kiniksa Pharmaceuticals Provides Corporate and Portfolio Update
January 8, 2023
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
November 29, 2022
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
November 22, 2022
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 31, 2022
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
October 30, 2022
Kiniksa Pharmaceuticals Announces Closing of Global License Agreement with Genentech for Vixarelimab
September 11, 2022
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
August 2, 2022
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 2, 2022
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
August 2, 2022
Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
August 1, 2022
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 2, 2022
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
May 1, 2022
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
February 21, 2022
Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
February 21, 2022
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
February 17, 2022
Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones
January 9, 2022
Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
January 2, 2022
Kiniksa Announces Results from Phase 3 Trial of Mavrilimumab in COVID-19-Related ARDS
December 27, 2021
Kiniksa Pharmaceuticals to Present at Evercore ISI 4th Annual HealthCONx Conference
November 22, 2021
Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution
October 31, 2021
Kiniksa Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 1, 2021
October 28, 2021
Kiniksa Pharmaceuticals to Present at 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 20, 2021
Kiniksa Announces Launch of ARCALYST Named Patient Program
August 15, 2021
Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
August 2, 2021
Kiniksa Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference
August 1, 2021
Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
July 19, 2021
Kiniksa Outlines Next Steps for the Development of Mavrilimumab
June 7, 2021
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
June 7, 2021
Kiniksa Pharmaceuticals to Present at Goldman Sachs 42nd Annual Global Healthcare Conference
May 31, 2021
Kiniksa Reports First Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity
May 3, 2021
Kiniksa Announces Positive Final Data from Phase 1 Trial of KPL-404
May 3, 2021
Kiniksa Announces Positive Results for Mavrilimumab Phase 2 Trial in Non-Mechanically Ventilated Severe COVID-19 Patients
April 11, 2021
Kiniksa Announces Commercial Availability of ARCALYST ® (rilonacept) for Recurrent Pericarditis
March 31, 2021
Kiniksa Announces FDA Approval of ARCALYST ® (rilonacept) for Recurrent Pericarditis
March 17, 2021
Kiniksa Launches Patient Registry (RESONANCE) for Recurrent Pericarditis
March 1, 2021
Kiniksa Reports Fourth Quarter and Full-Year 2020 Financial Results and Corporate and Pipeline Activity
February 22, 2021
Kiniksa Highlights Corporate Priorities and Expected 2021 Milestones
January 10, 2021
Kiniksa Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
January 3, 2021
Kiniksa Announces Data from U.S. Investigator-Initiated Study of Mavrilimumab in Severe COVID-19 Pneumonia and Hyperinflammation
December 21, 2020
Kiniksa Commences Dosing of Vixarelimab Phase 2b Clinical Trial in Prurigo Nodularis
December 14, 2020
Kiniksa Announces Preliminary Data from Phase 1 Trial of KPL-404
November 29, 2020
Kiniksa Pharmaceuticals to Present at the Evercore ISI 3rd Annual HealthCONx Conference
November 23, 2020